Manufacturing has been widely recognized as a bottleneck to bring advanced cell and gene therapies to the patients and families in need. The question is, should organizations stay the course internally, or look externally for their manufacturing needs?
Precision’s Alex Grosvenor will be presenting at World Pharma Pricing and Market Access Congress 2020 virtual. Don’t miss “Future Price and Market Access Considerations For Gene Therapies” on Friday, 25 September, 2020.
Join PRECISIONheor’s Jeroen Jansen, and partner David Phillippo, on Thursday, September 10th, 12:00pm EDT, as they provide an introduction to a novel method, called multilevel network meta-regression (ML-NMR). The method addresses several limitations with current methods, including synthesizing networks of any size and availability of IPD or aggregate studies, and – crucially for decision-making – producing estimates in any target population of interest.
Although there is a universal acknowledgement that health inequalities need to be addressed, the question is “How?” Precision’s Jason Shafrin and Meena Venkatachalam explain that simply incentivizing research and development efforts to create new drugs in therapeutic areas that disproportionately impact minorities won’t resolve the problem. Rather, we need to change traditional value assessment frameworks to move towards equity in health outcomes.
Current social and political events have brought renewed attention to the levels of systemic inequalities faced by millions of minorities in the United States and around the world. Adding to the discussion, Precision will explore how innovative health economics and outcomes research (HEOR) methods can be leveraged to quantify the full value new treatments that improve health outcomes for underserved communities.
As the first ‘big wave’ in the gene therapy space, onetime potentially curative treatments for hemophilia present a potential revolution for many thousands of patients. However, so far, gene therapies have targeted smaller indications and the prospect of treating much higher numbers at the price benchmarks already set may prove challenging for payers and health systems to provide access.
By Kathy Lang, PhD; Jason Shafrin, PhD
PRECISIONheor
What is the right price for a new treatment for COVID-19: ISPOR’s “value flower” or the traditional QALYs approach? Precision’s Jason Shafrin, Kathy Lang and Ross Maclean discuss why the “value flower” model can more accurately value treatments – in cases like COVID-19 – which have a transformational impact on the lives of not only of patients, but also caregivers, employers, and broader society.
As more Integrated Delivery Networks (IDNs) and employers move towards contracting directly with each other for health care services, the ripple effects are being felt in the supply chain and in old relationships with other players, including PBMs and pharmaceutical manufacturers. Precision’s Avi Mamidi discusses the benefits and obstacles of cutting out health insurance middlemen and moving towards direct employer-IDN partnerships.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
